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Reply
We would like to thank Drs. MacFadyen and Chuen for their interest
in our study (1). They seem to conclude that our population-based
report advocates screening for all persons with dyspnea. Unfortu-
nately, the majority of the issues they raise are based on this false
assumption. We believe that it is necessary to await the results from
studies evaluating the cost-effectiveness before introducing pro–B-
type natriuretic peptide (proBNP) as a screening tool of all breathless
persons in the community. We agree that if one sought to examine
the cost-effectiveness of the natriuretic peptides in primary care, they
should include the additional information that is obtainable for the
general practitioner.
The aim of our study was to examine whether or not plasma
proBNP could be used in discriminating between cardiac and pulmo-
nary dysfunction in the general population with dyspnea. Our findings
that plasma proBNP is increased in left ventricular dilation, hyper-
trophy, systolic and diastolic dysfunction, but unaffected by pulmonary
dysfunction, should be viewed in this perspective. Drs. MacFadyen
and Chuen also point out that 48% of the population in our study
reported dyspnea without having an abnormal conventional echocar-
diogram or pulmonary function test. It is important to emphasize that
a normal conventional echocardiogram does not rule out cardiac
dysfunction. Most of these people (83%) were only complaining of
mild dyspnea. Compared with their nondyspneic counterparts, they
had a higher frequency of ischemic heart disease and risk factors for
ischemic heart disease. Conventional echocardiography does not
provide much information about longitudinal myocardial contractility,
which is impaired initially in ischemic heart disease. In fact, we
suspect that breathless persons with a high level of plasma proBNP
have a high risk of cardiac dysfunction, although they might have
normal conventional echocardiograms. Further research with more
advanced modalities (e.g., tissue Doppler imaging) within such groups
is needed.
Intraindividual and interindividual variability of plasma
proBNP should not be extrapolated from studies of BNP or
N-terminal proBNP. The interindividual variability is one of the
major reasons for the assay’s gray zone reported in our study,
whereas the intraindividual variability of the assay is small (2).
Regarding the ability to rule out parenchymal lung disease by
spirometry, pulse oxymetry, and clinical history, we agree that
additional information from computed tomography scans and lung
biopsy would have been interesting but obviously not possible in
this population study. Concerning the last issue of pulmonary
hypertension in parenchymal lung disease, we have previously
shown that plasma proBNP only increases at elevated mean
pulmonary artery pressures 50 mm Hg in patients with terminal
parenchymal lung disease (3).
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Plaque Burden,
Intravascular Ultrasound, and
Distal Embolization Phenomenon
Although embolization of atherothrombotic material during stent
deployment is probably ubiquitous, its causes and consequences
remain poorly characterized. In a recent issue of the Journal, both
Kawaguchi et al. (1) and Kawamoto et al. (2) suggested that vessels
most likely to sustain distal embolization could be identified using
virtual histology (VH) intravascular ultrasound (IVUS) to quantify
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the necrotic core. It was suggested that patients with plaques
exhibiting these characteristics might benefit from selective use of
distal protection devices. Neither study suggested that a relation-
ship exists between original plaque volume and the occurrence of
embolization.
In our opinion, these studies have a number of limitations.
Kawaguchi et al. (1) chose ST-segment re-elevation immediately
after stent implantation as a proxy for embolization. This param-
eter has not previously been linked to the more recognized end
points of myocardial blush grade or 90-min ST-segment resolution
(3). Additionally, the limited ability of the 20-MHz Eagle Eye
IVUS catheter (Volcano Therapeutics, San Diego, California) to
identify luminal thrombus may be particularly relevant in their
patients who received only aspirin as a procedural antiplatelet
therapy. Moreover, the possibility of side branch occlusion during
stent deployment as a cause of myocardial necrosis does not appear
to have been considered. In patients with stable angina, Kawamoto
et al. (2) suggested that plaques with larger necrotic cores were
more likely to exhibit high-intensity transient signals detected by a
Doppler guidewire. Histopathological correlates between VH-IVUS
and pathology are questionable, and neither study uses post-
procedure IVUS imaging of residual plaque. Using 40-MHz IVUS
imaging, a direct relationship has been demonstrated between the
change in plaque volume and evidence of new myocardial necrosis
(4). Thus, although it is perhaps intuitive that friable plaque
elements are more likely to be liberated than are more readily
compressed fibrotic components, further investigation is required.
In the accompanying editorial, Shah (5) questions whether no
reflow is merely a marker of myocardial injury or whether it is the
cause of further myocardial damage. There is currently no data to
support the notion that, in established no reflow, administration of
any pharmacologic agent has any impact on subsequent prognosis,
and perfusion in areas of new myocardial necrosis remains im-
paired for at least 24 h despite normal perfusion in viable areas of
myocardium subtended by the same vessel (6). These data suggest
that no reflow is predominantly a marker of downstream myocar-
dial necrosis. As more diffuse and challenging diseases are being
tackled by percutaneous coronary intervention (PCI), further
research into the prevention of plaque embolization is essential to
allow further improvement in PCI outcomes.
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Reply
We appreciate the interest in our recent study (1) by Dr. Porto and
colleagues. Myocardial blush grade (MBG) and early ST-segment
resolution are well-known parameters used for describing the
effectiveness of myocardial reperfusion, which is an independent
predictor of long-term mortality (2). However, the aim of our
study was to investigate distal embolization that occurs immedi-
ately after stent implantation: in other words, distal embolization
induced by stent implantation. Although stent-induced distal
embolization is one of the causes of low blush grade or early
ST-segment resolution, it is not the only cause—several factors
such as vasoconstriction, additional pharmacologic therapy, and
time interval after stent implantation may also affect the outcome
of these parameters. Because we were not investigating final
coronary flow and prognosis, we believed that we did not need to
consider the relationship between ST-segment re-elevation (STR)
and MBG or early ST-segment resolution. Thus far, we have not
come across parameters specific to estimating the extent of
stent-induced distal embolization, and certainly, as we mentioned
in the limitations section, we need to validate our measurements in
a different cohort to see how the predictive algorithm correlates
with STR. However, STR during percutaneous coronary interven-
tion is recognized as a predictor of the no-reflow phenomenon
(3,4). In the no-reflow cases, distal embolization of the plaque or
thrombus from the lesion site is a likely mechanism (5,6). There-
fore, distal embolization of the plaque or thrombus from the lesion
site induced by stent deployment is the probable cause of STR.
Based on these data, we believe that STR occurring immediately
after stent implantation reflects distal embolization induced by
stent implantation.
We had mentioned in the limitations section about the presence
of residual luminal thrombus and the ability of the 20-MHz
intravascular ultrasound catheter to assess the plaque component.
Moreover, we did not have any cases with side branch occlusion in
the 11 STR cases, and it should have been included in the
exclusion criteria of our study.
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